Companies
Rapid Micro Biosystems
the Growth Direct platform automates colony detection for rapid sterility testing, validated against a comprehensive organism panel under USP <1223>, Ph. Eur. 5.1.6 and PDA Technical Report 33 to demonstrate detection capability equivalent to classical methods.
- Country
- United States
- Ticker
- NASDAQ:RPID
NASDAQ:RPID
Commercial
Coverage
| CN | EU | US | |
|---|---|---|---|
| analytics-pat | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Funding | Raised approximately $8.8 million in net proceeds through an underwritten offering and $0.1 million in a director and officer offering in May 2026 | sec.gov · stocktitan.net |
| Capacity | Company has significant manufacturing capacity including a fully automated consumables line and assembly capacity for systems and does not view manufacturing as a limiting factor for growth | longbridge.com |
| Certification | Growth Direct system is designed to align with international regulatory standards including 21 CFR Part 11 for digital records and audit trails, with manufacturing subject to ISO certifications | rapidmicrobio.com · sec.gov |
| Regulatory approval | Technology and validation strategy accepted by FDA and EMA for use in new drug applications; validated against USP <1223> and Ph. Eur. 5.1.6 standards | rapidmicrobio.com · sec.gov |
| Production site | Primary manufacturing facility in Lowell, Massachusetts, with a back-up facility for consumables in Lexington, Massachusetts | investors.rapidmicrobio.com · sec.gov |
| Headcount | 171 full-time employees as of December 31, 2025 | sec.gov |
| Revenue | Total revenue was $33.6 million for the full year 2025 and $8.05 million for the second quarter of 2026 | investors.rapidmicrobio.com · stocktitan.net |
Independent sources: investors.rapidmicrobio.com · longbridge.com · sec.gov · stocktitan.net
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Sterility testing systems | analytics-pat | Low | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.